Drug Exposure Articles & Analysis
11 news found
Lenalidomide has been an effective immunomodulatory drug in hematologic malignancies for years, however adverse events, notably neutropenia, have limited its use in certain patient settings. ...
Shanghai Ruijin Hospital recently announced that it has initiated an investigator-initiated clinical trial (IIT) to evaluate the safety and efficacy of Bofutrelvir administered by inhalation for post-exposure prophylaxis in close contacts of COVID-19 (NCT05415241). It is a single-arm, open-label, multi-dose exploratory clinical study with an enrolment of ~60 subjects who are ...
Axial believes this gut-targeted approach minimizes the potential for side effects in part due to a lack of systemic exposure to the drug. About The TAPESTRY Study Axial is evaluating AB-2004 in the TAPESTRY study, a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial to assess the efficacy, safety, and tolerability of the ...
Results from initial CY6463 clinical studies have demonstrated favorable safety and tolerability and pharmacologically relevant drug exposure in the cerebral spinal fluid. Furthermore, promising impacts on EEG measures, neuroinflammation, and other measures support the current clinical development of CY6463. ...
Key findings from the Phase 1b/2a trial include: AB-2004 was shown to have strong safety and tolerability across all dose levels, and no drug-related serious adverse events were identified. AB-2004 showed target engagement as measured by significantly reduced levels of key gut bacterial metabolites, including 4-ethylphenyl sulfate (4EPS), in both urine and plasma. ...
Axial’s gut-targeted approach minimizes the potential for side effects due to a lack of systemic exposure to the drug. Axial is evaluating AB-2004 in a Phase 2b clinical trial based upon a large body of existing human safety data. In a Phase 1b/2a clinical trial, AB-2004 was safe and well-tolerated, exhibiting no drug-related serious ...
Axial’s gut-targeted approach minimizes the potential for side effects due to a lack of systemic exposure to the drug. Axial is evaluating AB-2004 in a Phase 2b clinical trial based upon a large body of existing human safety data. In a Phase 1b/2a clinical trial, AB-2004 was safe and well-tolerated, exhibiting no drug-related serious ...
In addition, the funds will be used to drive forward the company’s drug discovery programs based on the company’s platform in the microbiome gut-brain axis. ...
Evaluation of antiprogestin pharmacology and pharmacokinetic data suggested that liver enzyme elevations might be related to off-target or metabolic effects associated with clinical drug exposure. Objective We explored whether the use of a pharmaceutic strategy targeting efficacious systemic dose concentrations, but with diminished peak serum concentrations ...
“This study, in addition to several of our other recent studies,” Clarke says, “shows that NASH, either alone or in combination with genetic differences in drug transporters, can have a profound effect on drug exposure.” Cherrington notes that this study is about the mechanism explaining how NASH changes the body’s ...
According to a new survey commissioned by Seventh Generation, the nation"s leading brand of environmentally responsible household and personal care products, half of all parents surveyed expressed more concern for the spread of germs (51 percent) than exposure to drugs/alcohol (28 percent) and poor grades (45 percent). The Seventh Generation Back to School ...